ATC Group: H01B Posterior pituitary lobe hormones

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of H01B in the ATC hierarchy

Level Code Title
1 H Systemic hormonal preparations, excl. Sex hormones and insulins
2 H01 Pituitary and hypothalamic hormones and analogues
3 H01B Posterior pituitary lobe hormones

Group H01B contents

Code Title
H01BA Vasopressin and analogues
H01BB Oxytocin and analogues

Active ingredients in H01B

Active Ingredient

Carbetocin selectively binds to oxytocin receptors in the smooth muscle of the uterus, stimulates rhythmic contractions of the uterus, increases the frequency of existing contractions, and raises the tone of the uterus musculature.

Desmopressin is a structural analogue of vasopressin in which the antidiuretic activity has been enhanced by the order of 10, while the vasopressor effect has been reduced by the order of 1500. The clinical advantage of this highly changed ratio of antidiuretic to vasopressor effect is that clinically active antidiuretic doses are far below the threshold for a vasopressor effect.

Oxytocin is a cyclic nonapeptide that is obtained by chemical synthesis. This synthetic form is identical to the natural hormone that is stored in the posterior pituitary and released into the systemic circulation in response to suckling and labour.

Terlipressin inhibits portal hypertension with simultaneous reduction of blood circulation in portal vessels. Terlipressin contracts smooth oesophageal muscle with consecutive compression of oesophageal varices.

The antidiuretic action of vasopressin is ascribed to increase in reabsorption of water by the renal tubules. Vasopressin can cause contraction of smooth muscle of the gastrointestinal tract, gall bladder, urinary bladder and all parts of the vascular bed, especially the capillaries, small arterioles and venules with less effect on the smooth musculature of the large veins. The direct effect on the contractile elements is neither antagonised by adrenergic blocking agents nor prevented by vascular denervation.

Related product monographs

Document Type Information Source  
 DDAVP DESMOPRESSIN Solution for injection MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 DDAVP MELT Oral lyophilisate MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 DESMOSPRAY Nasal spray, solution MPI, EU: SmPC Health Products Regulatory Authority (IE)
 DESMOTABS Tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 DURATOCIN Solution for injection MPI, CA: SPM Health Products and Food Branch (CA)
 HAEMOPRESSIN Powder and solvent for solution for injection MPI, EU: SmPC Health Products Regulatory Authority (IE)
 NOCDURNA Orally disintegrating tablet MPI, CA: SPM Health Products and Food Branch (CA)
 OCTIM Nasal spray MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 OCTOSTIM Solution for injection MPI, CA: SPM Health Products and Food Branch (CA)
 OFOST Solution for injection/infusion MPI, EU: SmPC Health Products Regulatory Authority (IE)
 PABAL Solution for injection MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 SYNTOCINON Concentrate for solution for infusion MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 VARIQUEL Solution for injection MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)